



**AVIVA PLC AND AVIVA INVESTORS GLOBAL SERVICES LIMITED PROVIDE NOTIFICATION
OF A 5.02% SHAREHOLDING IN ABLYNX**

GHENT, Belgium, 3 March 2015 – **Ablynx [Euronext Brussels: ABLX]** today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of shareholdings from Aviva plc and Aviva Investors Global Services Limited.

The above shareholders notified that they have exceeded the 5% threshold and now hold 2,714,836 Ablynx shares (as compared to a 3.04% holding on 30 October 2013), which represent 5.02% of the current 54,130,105 outstanding shares of Ablynx.

The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings: Aviva plc (Parent Company), Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc), Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited), Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited).

Full versions of all transparency notifications are available on the website of Ablynx, under the section [Investors](#).

About Ablynx

[Ablynx](#) is a biopharmaceutical company engaged in the development of [Nanobodies®](#), proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than [30 proprietary and partnered programmes](#) in development in therapeutic areas including inflammation, haematology, oncology and respiratory disease. The Company has collaborations and significant partnerships with pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact:

Ablynx:

Dr Edwin Moses

CEO

t: +32 (0)9 262 00 07

m: +32 (0)473 39 50 68

e: edwin.moses@ablynx.com

Marieke Vermeersch

Associate Director Investor Relations

t: +32 (0)9 262 00 82

m: +32 (0)479 49 06 03

e: marieke.vermeersch@ablynx.com

[@AblynxABLX](#)



Ablynx media relations Consilium Strategic Communications:

Mary-Jane Elliott, Jonathan Birt, Chris Welsh, Lindsey Neville

t: +44 203 709 5700

e: ablynx@consilium-comms.com

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.